association between a positive reaction. in. the test and protection from coronary heart disease.
Patients, methods, and results
We examined 36 non-insulin dependent diabetics originally identified in 1979-81 ini a study of 1.33 newly diagnosed diabetics aged 45-64 years who were representative of the diabetic population of Kuopio, Finland. In the original study population 23 diabetics had a history of myocardial infarction verified at hospital or electrocardiographic abnormalities diagnostic of previous myocardial infarction (Minnesota code 1-1-1-2) and 21 diabetics were free of coronary heart disease by strict criteria (absence of chest pain by Rose cardiovascular questionnaire and normal electrocardiogram). These two groups of diabetics were invited to participate in this study and, finally, 20 diabetics with previous myocardial infarction (coronary heart disease group) and 16 diabetics free of coronary heart disease took part. The coronary heart disease group comprised nine men and 11 women, and the other group 10 menr and six women. Of all 36 patients, 27 were being treated with diet, seven with sulphonylureas, and two with metformin.
The chlorpropamide-alcohol flushing test was performed in a room kept at a constant 20-22°C. Patients were given 40 ml of sherry 12 hours after 250 mg of chlorpropamide. Temperature of the face was measured by a digital thermometer with a resolution of 0-1°C. Facial warmth, flushing, or burning of the face were regarded as subjective evidence of a positive reaction. An increase of over 1°C in skin temperature 30 minutes after the sherry was taken as objective evidence of a positive reaction.
Plasma insulin concentration was determined by radioimmunoassay (Novo, Denmark) before and one and two hours after a 75 g oral glucose load. Serum total cholesterol and triglyceride concentrations were estimated by enzymatic methods. Serum high density lipoprotein cholesterol was determined fromr. supernatant after precipitation by dextran sulphate and magnesium chloride Serum chlorpropamide concentration was measured by high performance liquid chromatography.4 The y2 test and Student's two tailed t test were used for statistical analyses.
Of the 16 diabetics without coronary heart disease and the 20 with a history of heart disease, four and six, respectively, gave subjective evidence of flushing (difference not statistically significant'. Objective evidence of flushing was obtained in six patients in each group (difference not significant).
Use of other criteria for a rise in skin temperature (increase of 15'C or more 30 minutes after sherry or a maximal increase of 2?C or more, or both; and a maximal temperature rise of over 1IC) also showed no statistically significant difference in the prevalence of chlorpropamide-alcohol flushing between the groups.
Comparison of subjects with and without evidence of flushing showed no statistically significant differences in age, relative weight, serun'r concentrations of cholesterol, high density lipoprotein cholesterol, and triglycerides, plasma insulin concentration, or serum chlorpropamide concentration. The table summarises these results. In the coronary heart disease group flushers had lower high density lipoprotein cholesteroi concentrations than had the non-flushers (p < 0 005).
Comment
Our results dicl not confirm reports2 5 of an association between chlorpropamide-alcohol flushing and a diminished risk of large vessel disease. Contradictory results may be explained by differences in the selection and treatment of diabetics, by differences in the definition of large vessel complications studied, and by different criteria used to define a positive reaction in the chlorpropamidealcohol flushing test,
The test was carried out in two groups of non-insulin dependent diabetics who hac! been included in a larger population based survey. The presence or absence of coronary heart disease was determined by strict criteria, None of the diabetics was receiving chlorpropamide as maintenance treatment. Long term chlorpropamide increases the proportion of patients giving positive reactions in the test5 and is thus a confounding factor in studies correlating chlorpropamidealcohol flushing with small vessel or large vessel complications.
Our Bronchoconstriction in response to ipratropium bromide Ipratropium bromide is a new anticholinergic compound that is used increasingly to treat patients with limited airflow obstruction. Paradoxically, however, it may cause bronchoconstriction in occasional patients with atopic asthma.' It has been suggested that this bronchoconstrictor response may result from increased viscosity of sputum in the airways' or perhaps from altered bronchial reactivity to anticholinergic drugs in these patients. ' We report on a patient with extrinsic bronchial asthma who responded adversely to inhaled ipratropium bromide. We challenged the patient with two concentrations of ipratropium bromide and compared the effects with those of inhaled isotonic saline, atropine methonitrate, and sodium bromide solution to investigate the mechanism concerned.
Case report While participating in a pharmacological study a 34 year old woman with atopic asthma and eczema developed pronounced and prolonged bronchoconstriction after inhalation of ipratropium bromide nebuliser solution (1 g/l isotonic saline) given through a Wright nebuliser. Her asthma was well controlled with sodium cromoglycate 20 mg four times a day, and she used salbutamol aerosol 200 Jig as required for symptomatic relief. All her drugs had been stopped 12 hours previously.
She was asked to attend on five afternoons after having stopped her drugs for at least 12 hours. Forced expiratory volume in one second was recorded with a water sealed spirometer (Godart Pulmotest). After a stable baseline reading had been obtained she was made to inhale ipratropium bromide (0-25 g/l or 1 g/l), atropine methonitrate (10 g/l), sodium bromide (0-25 g/l), or isotonic saline through a Wright nebuliser at tidal breathing for five minutes. Ipratropium bromide, atropine, and sodium bromide were all dissolved in isotonic saline, and treatments were carried out in a single blind fashion. Forced expiratory volume in one second was recorded at one, three, four, seven, 10, 15, 20, 25 , and 30 minutes after inhalations. She developed severe bronchoconstriction after inhaling ipratropium bromide (at both concentrations) and sodium bromide; isotonic saline did not cause any change from the baseline value of forced expiratory volume in one second (figure). Bronchodilatation occurred after inhalation of atropine methonitrate, the maximal increase in forced expiratory volume in one second being 33%,, at 20 minutes; this increase was still present at 30 minutes. 
This patient developed bronchoconstriction within a minute after inhaling ipratropium bromide, with an appreciable fall in the forced expiratory volume in one second. A similar response was observed after challenge with sodium bromide solution. In contrast, she showed bronchodilatation after inhaling atropine methonitrate. The bronchoconstrictor response to ipratropium bromide was unlikely to have been due to changes in sputum viscosity or an altered bronchial reactivity to inhaled anticholinergic drugs as she did not show a similar response to atropine. Furthermore, the drugs were dissolved in isotonic saline to avoid airways responses induced by hypotonic and hypertonic solutions.3 The bronchoconstriction was most probably related to an adverse reaction to bromide. It is difficult, however, to postulate whether bromide acts directly on the bronchial smooth muscle or the vagal receptors or causes non-specific degranulation of mast cells.
